JP Morgan Chase’s Akcea Therapeutics Inc AKCA Stock Holding History

JP Morgan Chase’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-22,500	Closed	-$346K	–	6020
2019 Q3	$346K	Buy	22,500 +4,100	+22%	+$87.3K	﹤0.01%	4353
2019 Q2	$425K	Sell	18,400 -176,600	-91%	-$4.36M	﹤0.01%	4308
2019 Q1	$5.52M	Buy	195,000 +1,500	+0.8%	+$43.7K	﹤0.01%	2508
2018 Q4	$5.83M	Buy	193,500 +148,500	+330%	+$4.16M	﹤0.01%	2447
2018 Q3	$1.58M	Sell	45,000 -9,000	-17%	-$272K	﹤0.01%	3626
2018 Q2	$1.28M	Buy	+54,000	New	+$1.29M	﹤0.01%	3684

JP Morgan Chase's AKCA Position: Q4 2020 in Review

JP Morgan Chase sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 6,134 shares — an estimated $111K sold.

JP Morgan Chase first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $152K in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

JP Morgan Chase reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
JP Morgan Chase sold 6,134 Akcea Therapeutics Inc shares in Q4 2020, an estimated $111K.
JP Morgan Chase first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
JP Morgan Chase's Akcea Therapeutics Inc position peaked at $152K in Q3 2018.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.